Brief: Cosmo: successful outcome of phase III clinical trial for Rifamycin SV MMX
06/06/2016 06:01
June 6 (Reuters) - Cosmo Pharmaceuticals SA COPN.S :
* Cosmo announces successful outcome of phase III clinical trial for Rifamycin SV MMX
Source text for Eikon: ID:nTEN9s84ra
Further company coverage: COPN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Cosmo Ferrites
See all newsIndia's Cosmo Ferrites jumps on anti-dumping duty on Chinese imports
Brief: Cosmo Ferrites Says Anti-Dumping Duty Expected To Improve Capacity Utilization And Operating Margins
Brief: Cosmo Ferrites Reappoints Ambrish Jaipuria As MD
Brief: Cosmo Ferrites Entered Into An Agreement With Cosmo First
Brief: Cosmo Ferrites Appointed Rishab Jain As CFO